2C-T-29

2C-T-29
Identifiers
  • 2-(2,5-dimethoxy-4-prop-2-ynylsulfanylphenyl)ethanamine
PubChem CID
Chemical and physical data
FormulaC13H17NO2S
Molar mass251.34 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)SCC#C
  • InChI=1S/C13H17NO2S/c1-4-7-17-13-9-11(15-2)10(5-6-14)8-12(13)16-3/h1,8-9H,5-7,14H2,2-3H3
  • Key:BWTBPZDUQOTNBE-UHFFFAOYSA-N

2C-T-29 (2C-T-PROPARGYL) is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a potent agonist at the serotonin receptor 5-HT2A in vitro, with a binding affinity (Ki) of 1.3 nM and an EC50 of 0.67 nM, acting as a full agonist.[1] While the closely related propylthio compound 2C-T-7 and the allylthio derivative 2C-T-16 are both known to be potent psychedelic drugs in humans, the propargylthio analogue 2C-T-29 is not known to have been tested in humans or other animals.[2]

See also

[edit]

References

[edit]
  1. ^ Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". Journal of Medicinal Chemistry. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
  2. ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion. Nachtschatten Verlag AG. pp. 792–795. ISBN 978-3-03788-700-4.